Research programme: KRAS inhibitors - Carmot Therapeutics
Latest Information Update: 01 Feb 2024
Price :
$50 *
At a glance
- Originator Carmot Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
- 03 Jul 2023 Discontinued for Cancer in USA (unspecified route) (Carmot Therapeutics pipeline, July 2023)
- 10 Feb 2021 Research programme: KRAS inhibitors - Carmot Therapeutics is available for licensing as of 10 Feb 2021. https://carmot-therapeutics.us/partnerships/